LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Meta Expands AI Training With Employee Activity Tracking Tools 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
WALTHAM, Mass., March 17, 2017 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the Oppenheimer 27th Annual Healthcare Conference in New York City on Wednesday, March 22, 2017 at 1:35 p.m. ET.
A live audio webcast of the presentation can be accessed by visiting the Investor and Media section of the Company’s website at www.proteontherapeutics.com. A replay of the webcast will be archived on the Proteon website following the presentation.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
[email protected]
